AIM Immunotech vs Virax Biolabs Group
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $12,423 for Virax Biolabs Group (7.1 times as much). Virax Biolabs Group grew faster (96.2% against -48.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -40439.1%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Virax Biolabs GroupVRAX, 2026 |
|---|---|---|
| Revenue | $88,000 | $12,423 |
| Revenue growth | -48.2% | 96.2% |
| Net income | −$14.0m | −$5.0m |
| Operating margin | -13254.5% | -51515.2% |
| Net margin | -15861.4% | -40439.1% |
| Return on equity | — | -75.7% |
| Free cash flow | −$11.0m | −$4.9m |
| Cash | $3.0m | $6.4m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | — |
| Market value | $4.7m | $613,971 |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | — |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |